

**1° Meeting Italiano Internazionale Congiunto
IPOHA Onlus e Fop Italia Onlus**

1st International Italian Joint Meeting on POH and FOP

20-21 marzo 2009
Cerignola (FG)

Renata Bocciardi

S.C. Genetica Molecolare e Citogenetica
Laboratorio di Genetica Molecolare
Istituto G. Gaslini
Genova

Summary of the clinical features and molecular analysis of the presented FOP patients set.


| | Pt | Age | Sex | Age Ossification onset | Great toe malf. | Mutation | Other |
|----|-------|------|-----|------------------------|-----------------|----------------------------------|--|
| 1 | FOP1 | 33 y | M | na | y | c.617G>A, nd | |
| 2 | FOP2 | 5 y | M | 15 months | y | c.617G>A, <i>de novo</i> | Hydrocephalus secondary to a posterior bulbar expansive lesion of unknown origin (surgical correction) |
| 3 | FOP3 | 10 y | F | 4 y | y | c.617G>A, <i>de novo</i> | |
| 4 | FOP4 | 5 y | F | 20 months | y | c.617G>A, <i>de novo</i> | |
| 5 | FOP5 | n.a. | M | 8 y | y | c.617G>A, nd | |
| 6 | FOP6 | 29 y | F | 6 y | y | c.617G>A, nd | |
| 7 | FOP7 | 28 y | F | 11 y | y | c.617G>A, nd | |
| 8 | FOP8 | 50 y | F | 11 y | y | c.617G>A, nd | |
| 9 | FOP9 | 45 y | M | 3 y | y | c.617G>A, nd | |
| 10 | FOP10 | 36 y | M | 14 y | y | c.617G>A, nd | |
| 11 | FOP12 | 9 y | M | 6 months | y | c.617G>A, nd | |
| 12 | FOP13 | 22 y | F | 4 y | No | c.774G>C, <i>de novo</i> , R258S | c.44C>G dbSNP rs13406336, inherited |
| 13 | FOP14 | 49 y | M | 5 y | y | c.617G>A, nd | Episodic seizures |
| 14 | FOP15 | 37 y | M | 4 | y | c.617G>A, nd | |
| 15 | FOP17 | 9 y | M | 6 y | y | c.617G>A, nd | |
| 16 | FOP18 | 17 y | F | na | Short hallux | c.617G>A, nd | Fusion of C4-C5, osseous dysplasia |
| 17 | FOP20 | 44 y | F | 14 y | No | c.774G>C, <i>de novo</i> , R258S | Vitamin D deficiency, thyroid goiter |
| 18 | FOP22 | 38 y | F | 9 months | y | c.617G>A, nd | |
| 19 | FOP23 | 11 y | M | 5 y | hypoplastic | c.617G>A, nd | Neck stiffness, NOGGIN neg |
| 20 | FOP24 | 13 y | M | 13 y | y | c.619C>G, <i>de novo</i> , Q207E | Malformed shortened thumbs |

Pt, patient code; nd, mutation origin not determined; na, not available; 26 patients have been screened, 20 with confirmation of the clinical diagnosis, see table, 6 with exclusion of FOP

Study of the regulation of *ACVR1* expression

Characterization of the structure and composition of the *ACVR1* transcripts.

Definition and characterization of genomic regions playing a role in the regulation of *ACVR1* expression, such as gene promoter/s and/or other sequences with regulatory activity.



✓ **Characterization of the structure and composition of the *ACVR1* transcripts.**

Definition and characterization of sequences playing a role in the regulation of *ACVR1* expression.

➤ **5' UTR sequences**

➤ Promoter region

➤ **3' UTR region**

Characterization of the structure and composition of the *ACVR1* transcripts

How many are *ACVR1* transcripts?

```

tgttgctgcc tggttaatca cagctccaga cactcattgg ccgagcgcctc 158441139
cgcagccact tcctcctcct cctcctcccg ctctcctccg tccggctcct 158441089
GCTCTTTGCA GCCGCGCCG CCGCGCAGC CTCCCCCTCG GCGCAGGGG 158441039
AACTTTTCTA CTCTCTGTGA CGGTCTCCCC CGCCGCCCCC GGGGGCAAGC 158440989
CCAGCTGGTC GCCTCCGCC GCGCGGGTC GTGCTCCAG cccgagcctc 158440939
tgcgcctcgg gaagtttatt ctgcccggcc tcctcccctt cctcctcctc 158440889
ttcaccocgc ctcccggccc tcccggget ctttcccocg ggtggctgcc 158440839
gctgcccggc ctgcccgtgc cagcctgtct ctggccagc cgcgcccggc 158440789
ccagggccgg gaagctccc gccccacgca ccgctccgct gcagccaccg 158440739
cagccgccgc cgtctggggc cggccctcgg ccccggctc cccgccccgc 158440689
agagttccgg gctccctcgc cggctgcacc gccccggccc gccccggccc 158440639
gccccggccc ggcgcgacCT GCAGCGCCG GCTGCCTCGC ACTCCGCCTC 158440589
CCCCGGCTCAG CCCCCGGCC GCGGCGGGAC CCGAGgtgag cgcaggtcgc 158440539
cggccgcgcc tgcctggagc gggaggactg agggaggagg tagcctagcg 158440489
ggagaagagg cagggatcgg gggggcagg gtgggcgtct gcggtgcctc 158440439
cccctcgctt tcattccttt ccccccaag cttgatcccc tctccgtggg 158440389
ggaagcagcc gcggaacaaa actgtcttgc tttgggcctg aactgctggt 158440339
gggatatggg ggggtggggg gcagagcgt ggagcggggg tctcaggttt 158440289
gtattggggt gtgtgtgagt gctgtgtgt gtgtgtgtgt gttgtgaact 158440239
ccttcagggg gtgcgactct gacttgtaaa tcgatctggc cgcggggcca 158440189
cgggcttac cttcctagct gagctttag agagtaagga gatagatagg 158440139
cgaatttccc ccaccctcaa aatatccatc tcttccaaga ggaattttct 158440089
gctggagaga cagccaataa actctgctca actccctccc tccctcgggt 158440039
cttcctagct gcagtttcaa aaagcttcaa agccaggaat gtgggattca 158439989
tcttcogatc cccagaaggc aaatgtggtt acagatggtg cacggtactt 158439939
tgccaagttt aaaacccttc cttcaacact gtaaccacaaa cagtgaggct 158439889
agaacctcgg gcgcactaaG AAGAGATGTG GGCCTCTGG CCGCTGGAT 158439839
TCAGTAACTT CCGTCGGGTT CTAGACTGGC TCGGCTCTGT CCAGTTTGTG 158439789
CCAGATAGTC TCCCACCCCC TCCCACCCCC TCCTTTCCCC TGGAGATTG 158439739
AACGCTGCTT GCATGGGAGA AAAGCTACTT AGAGAAGAAA ACGTTCCACT 158439689
TAGTAACAGA AGAAAAGTCT TGGTTAAAAA GTTGTATGA ATTTGGCTTT 158439639
TGGAGAGAGG CAGCAAGGTa atacaatgga cttgtcaatt ttattgggct 158439589
tttctttctt ttttgaggga tgtatgataa gagttagatg atgggcaaa 158439539
//
ttagccacca cattcacaac tgcaggattt tcttctgctt agctggtttt 158383339
ctttcttctt tcctcttgca gCCTGGAGCA TTGGTAAGCG TCACACTGCC 158383289
AAAGTGAGAG CTGTGGAGA ACTCATAATC CCAGGAACGC CTCTTCTACT 158383239
CTCCGAGTAC CCCAGTGACC AGAGTGAGAG AAGCTCTGAA CGAGGCACG 158383189
CGGCTTGAAG GACTGTGGGC AGATGTGACC AAGAGCCTGC ATTAAGgtag 158383139
ctgagtaagc tttaccagg agctctcaga acggcattgc cagaaccagc 158383089
agtgcagcca cttaacaaa tcacttcttt taatactctt tggcagagat 158383039
//
ttacttacat ctcttctttt ccctttacag TTGTACAATG GTAGATGGAG 158364239
TGATGATTCT TCCTGTGCTT ATCATGATG CTCTCCCTC CCCTAGTATG 158364189
GAAGgtaagt gactcacatc tttttgggtt aagataagta tactgtgatt 158364139
ttttttttg gcttactata aactacttct taagcctatc aaacttaaaa 158364089
cactcttttt ataataataa tttggtgatt attgactatt ttgaaggaaa 158364039


```

~~EST
CN481300~~

RefSeq 1
NM_001111067.1




RefSeq 2
NM_001105.4




Two main *ACVR1* transcripts are detectable in cells expressing the gene and are present in Gene Bank.

These transcripts share an untranslated exon 2 and all the protein coding sequences, but show an alternative exon 1 probably due to the presence of two different transcription start sites.



However, we have identified a new transcript isoform showing an insertion of 116 bp between the untranslated exon 2 and first protein coding exon.




```

aattgaaagg cgtgccaaat gtgcacttcc tttagccacc acattcacia 158383370
ctgcagagatt ttctttctgct tagctggttt tctttcttct ttccctctgc 158383320
agCCTGGAGC ATTGGTAAGC GTCACACTGC CAAAGTGAGA GCTGCTGGAG 158383270
AACTCATAAT CCCAGGAACG CCTCTTCTAC TCTCCGAGTA CCCCAGTGAC 158383220
CAGAGTGAGA GAAGCTCTGA ACGAGGGCAC GCGGCTTGAA GGACTGTGGG 158383170
CAGATGTGAC CAAGAGCCTG CATTAAGgta gctgagtaag ctttacccag 158383120
gagctctcag aacggcattg ccagaaccag cagtgcagcc acttcaacia 158383070
atcacttctt ttaatactct ttggcagaga tcaaatctac agggtaaatt 158383020
ctttgccaca aatgattatt ttgttttttt atatgaatcc aatataagaa 158382970
agttaggacc agcctaatag ttcttagttc tggcgttgcc ttcatagtag 158382920
gctttgttgg gtggatctgc acagctattc tttaaatttg gccaaagttt 158382870
tcaaataaat actaccagtg tttccctgcc tataaaatgc ccctgccatc 158382820
cttttcacct tacagggcca ctacattaag tttttctttt cttttgtttt 158382770
//
ttacttacat ctcttctttt ccctttacag TTGTACAATG GTAGATGGAG 158364239
TGATGATTCT TCCTGTGCTT ATCATGATTG CTCTCCCCTC CCCTAGTATG 158364189
GAAGgtaagt gactcacatc tttttgggtt aagataagta tactgtgatt 158364139
tttttttttg gcttactata aactacttct taagcctatc aaacttaaaa 158364089
cactcttttt ataataaata tttggtgatt attgactatt ttgaaggaaa 158364039

```

This isoform is due to an alternative splicing leading to the incorporation of 116 bp of the 5' end of intron 3 in the mRNA.

The inserted sequence is highly conserved among species and is even more conserved than the adjacent exon.



This sequence can have a role at post-transcriptional level and we are currently investigating in this direction.

Characterization of the structure and composition of the *ACVR1* transcripts.

✓ **Definition and characterization of sequences playing a role in the regulation of *ACVR1* expression.**


➤ *5' UTR* sequences

➤ **Promoter region**


✓ *3' UTR* region

Identification and characterization of *ACVR1* promoter region

We are currently focusing on a region of 3400 bp upstream the *ACVR1* gene and spanning the two alternative first exons



Y. Yao et al. *Arterioscler. Thromb. Vasc. Biol.* 2008; 28:2266-2274
Described as promoter sequence a region upstream of the first protein coding exon . ??



Characterization of the structure and composition of the *ACVR1* transcripts.

Definition and characterization of sequences playing a role in the regulation of *ACVR1* expression.

➤ *5' UTR* sequences


➤ Promoter region

✓ ***3' UTR* region**

Analysis of the *ACVR1* 3' UTR

```


CATTTCATA GTGCAAGAA GGAAGATTTG ACGTTGTTGT CATTGTCCAG 50
CTGGGACCTA ATGCTGGCCT GACTGGTTGT CAGAATGGAA TCCATCTGTC 100
TCCCTCCCA AATGGCTGCT TTGACAAGGC AGACGTCGTA CCCAGCCATG 150
TGTTGGGGAG ACATCAAAAC CACCCTAACC TCGCTCGATG ACTGTGAACT 200
GGGCATTTCA CGAACTGTTT ACACCTGCAGA GACTAATGTT GGACAGACAC 250
TGTTGCAAAG GTAGGGACTG GAGGAACACA GAGAAATCCT AAAAGAGATC 300
TGGGCATTAA GTCAGTGGCT TTGCATAGCT TTCACAAGTC TCCTAGACAC 350
TCCCCACGGG AAACCTCAAGG AGGTGGTGAA TTTTAAATCA GCAATATTGC 400
CTGTGCTTCT CTTCTTTATT GCACTAGGAA TTCTTTGCAT TCCTTACTTG 450
CACTGTTACT CTTAATTTTA AAGACCCAAC TTGCCAAAAT GTTGGCTGCG 500
TACTCCACTG GTCTGTCTTT GGATAATAGG AATTCAATTT GGCAAAACAA 550
AATGTAATGT CAGACTTTGC TGCATTTTAC ACATGTGCTG ATGTTTACAA 600
TGATGCCGAA CATTAGGAAT TGTTTATACA CAACTTTGCA AATTATTTAT 650
TACTTGTGCA CTTAGTAGTT TTTACAAAAC TGCTTTGTGC ATATGTTAAA 700
GCTTATTTTT ATGTGGTCTT ATGATTTTAT TACAGAAATG TTTTAAACAC 750
TATACTCTAA AATGGACATT TTCTTTTATT ATCAGTTAAA ATCACATTTT 800
AAGTGCTTCA CATTTGTATG TGTGTAGACT GTAACTTTTT TTCAGTTCAT 850
ATGCAGAACG TATTTAGCCA TTACCCACGT GACACCACCG AATATATTAC 900
TGATTTAGAA GCAAAGATTT CAGTAGAATT TTAGTCCTGA ACGCTACGGG 950
GAAAATGCAT TTTCTTCAGA ATTATCCATT ACGTGCATTT AAACCTCTGCC 1000
AGAAAAAAT AACTATTTTG TTTTAAATCTA CTTTTTGTAT TTAGTAGTTA 1050
TTTGTATAAA TTAAATAAAC TGTTTTCAAG TCAAAAaaaa aaaaaaaaaa 1100
    
```



❖ Subcloning of *ACVR1* 3' UTR region downstream the coding sequence of the firefly Luciferase reporter gene.

❖ Evaluation of the Luciferase activity compared to that of the pGL3-prom empty vector in different cell lines.

pGL3-promoter vector empty *versus* pGL3-prom ACVR1 3'UTR



- The presence of the 3'UTR sequence of *ACVR1* causes a decrease in the activity of the reporter gene (Luciferase) in all the tested cell lines.
- 3'UTR sequence of *ACVR1* can be target of different mechanisms of post-transcriptional regulation.

The expanding universe of RNA

It is now clear that different levels of regulation in gene expression do exist.

3% coding RNA

97% non-coding RNA

housekeeping RNA (rRNA, tRNA, snRNA,...)


regulatory RNA (scRNA, siRNA, gRNA, microRNA...)

Recently, a growing body of the literature has focused on the role of microRNAs (miRNAs) as crucial players of post-transcriptional regulation of gene expression, both in physiological conditions (development, differentiation, growth, etc.) and in disease (cancer, inflammation, etc.).

microRNA

MicroRNAs are small 20-22 nt non-coding RNA that play important gene-regulatory roles in animals and plants by pairing to the 3'UTR mRNAs of protein-coding genes. Around 30% of human genes is expected to be regulated by the action of microRNA.

They have a pleiotropic effect, a single microRNA can modulate several genes. A single gene can be targeted by several microRNAs involved in the fine tuning of its expression.



microRNAs can bind the 3'UTR sequences of protein coding genes at specific sites

Gene silencing
✓ mRNA degradation
✓ Translational repression

Positive regulation
mRNA stability

Role of miRNA in post-transcriptional regulation of *ACVR1*

Different web-based tools are now available to scan sequences for the presence of putative microRNA binding sites.

| | |
|--------------------|--|
| TargetScan: | http://www.targetscan.org |
| PicTar: | http://pictar.mdc-berlin.de/ |
| miRbase: | http://microrna.sanger.ac.uk |


ACVR1 and microRNA



<http://www.targetscan.org>

Release 5.0: December 2008


Human ACVR1 3' UTR



Gene

Human ACVR1 NM_001105 3' UTR length:1083

Conserved sites for miRNA families broadly conserved among vertebrates



Conserved sites for miRNA families conserved only among mammals



miR-300

[Hide Conserved sites for miRNA families conserved only among mammals]
[Show poorly conserved sites and sites for poorly conserved miRNA families]
[View SVG image of miRNA sites]
[View table of miRNA sites]

Key:

Sites with higher probability of preferential conservation
8mer 7mer-m8 7mer-1A 3' comp*
Sites with lower probability of preferential conservation
8mer 7mer-m8 7mer-1A 3' comp*

***In silico* analysis revealed that several conserved putative binding sites for miRNA are predicted in the 3' UTR of the gene and need to be experimentally verified.**

TargetScan References:

- 1) Benjamin P Lewis et al., *Cell*, 120:15-20 (2005).
- 2) Andrew Grimson, et al., *Molecular Cell*, 27:91-105 (2007).
- 3) Robin C Friedman et al., *Genome Research*.

How to choose microRNA to be tested?

- microRNA with binding sites highly conserved among species.
- Binding sites recognized by different programs.
- Candidate microRNA.

Binding sites recognized
by 3 programs

| Micro RNA | PicTar | TargetScan | |
|---|--------|------------|---------------|
| hsa-miR-301a: 405 432 | P | T | -14.46/-19.81 |
| hsa-miR-130a: 406 435 | P | T | -16.35/-18.22 |
| hsa-miR-148a: 406 434 | P | T | -11.18/-12.05 |
| hsa-miR-182: 458 | P | T | -12.34 |
| hsa-miR-152: 436 | P | T | -12.21 |
| hsa-miR-384: 412 | P | T | -11.47 |


Binding sites recognized
by at least 2 programs

| Micro RNA | PicTar | TargetScan | |
|---|--------|------------|---------------|
| hsa-miR-130b: 403 433 | P | | |
| hsa-miR-301a: 405 432 | P | T | -14.46/-19.81 |
| hsa-miR-130a: 406 435 | P | T | -16.35/-18.22 |
| hsa-miR-30c: 576 605 | P | | -15.92/-12.22 |
| hsa-miR-365: 185 290 | | T | -10.25/-14.17 |
| hsa-miR-137: 372 | | T | -13.49 |
| hsa-miR-148a: 406 434 | P | T | -11.18/-12.05 |
| hsa-miR-30d: 576 | P | | -16.4 |
| hsa-miR-30e: 576 | P | | -14.28 |
| hsa-miR-182: 458 | P | T | -12.34 |
| hsa-miR-152: 436 | P | T | -12.21 |
| hsa-miR-384: 412 | P | T | -11.47 |
| hsa-miR-148b: 435 | P | | -11.8 |
| hsa-miR-381: 798 | | T | -13.59 |

```

CATTTCATA GTGTCAAGAA GGAAGATTG ACGTTGTTGT CATTGTCCAG 50
CTGGGACCTA ATGCTGGCCT GACTGGTTGT CAGAATGGAA TCCATCTGTC 100
TCCCTCCCCA AATGGCTGCT TTGACAAGGC AGACGTCGTA CCCAGCCATG 150
TGTTGGGGAG ACATCAAAAC CACCCTAACC TCGCTCGATG ACTGTGAACT 200
miR-365
GGGCATTTCA CGAACTGTTT ACACTGCAGA GACTAATGTT GGACAGACAC 250
TGTTGCAAAG GTAGGGACTG GAGGAACACA GAGAAATCCT AAAAGAGATC 300
miR-365
TGGGCATTAA GTCAGTGGCT TTGCATAGCT TTCACAAGTC TCCTAGACAC 350
miR-137
TCCCCACGGG AAACCTCAAGG AGGTGGTGAA TTTTAAATCA GCAATATTGC 400
miR-130a/b miR-384 miR130/301/148/152
CTGTGCTTCT CTTCTTTATT GCACTAGGAA TTCTTTGCAT TCCTTACTTG 450
miR-182
CACTGTTACT CTTAATTTTA AAGACCCAAC TTGCCAAAAT GTTGGCTGCG 500
miR-384
TACTCCACTG GTCTGTCTTT GGATAATAGG AATTCAATTT GGCAAAACAA 550
miR-30c/d/e
AATGTAATGT CAGACTTTGC TGCATTTTAC ACATGTGCTG ATGTTTACAA 600
miR-384
TGATGCCGAA CATTAGGAAT TGTTTATACA CAACTTTGCA AATTATTTAT 650
TACTTGTGCA CTTAGTAGTT TTTACAAAAC TGCTTTGTGC ATATGTTAAA 700
GCTTATTTTT ATGTGGTCTT ATGATTTTAT TACAGAAATG TTTTAAACAC 750
TATACTCTAA AATGGACATT TTCTTTTATT ATCAGTTAAA ATCACATTTT 800
miR-381/300
AAGTGCTTCA CATTTGTATG TGTGTAGACT GTAACTTTTT TTCAGTTCAT 850
ATGCAGAACG TATTTAGCCA TTACCCACGT GACACCACCG AATATATTAC 900
TGATTTAGAA GCAAAGATTT CAGTAGAATT TTAGTCCTGA ACGCTACGGG 950
GAAAATGCAT TTTCTTCAGA ATTATCCATT ACGTGCATTT AAACTCTGCC 1000
miR-381/300
AGAAAAAAT AACTATTTTG TTTTAACTTA CTTTTTTGTAT TTAGTAGTTA 1050
TTTGTATAAA TTAATAAAC TGTTTTCAAG TCAAaaaaaa aaaaaaaaaa 1100


```



❖ Cotransfection of pGL3-Prom- *ACVR1* 3'UTR with precursor of selected microRNA (pre-MIR, Ambion) in HeLa cells.

❖ Evaluation of the luciferase activity.

Expression of the selected microRNA in HeLa cells according to the microRNA Data Base (www.microrna.org)



HeLa cells show little, if any, expression of the selected microRNAs.

3' UTR - *ACVR1* and microRNA






Transfection protocol (24 wells plate)

Cells are plated and transfected at the same time


- 90 000 cells/well HeLa
- 400 ng GL3 or UTR
- 5 ng Renilla

- 15 pmoles miR precursor
- siPORT *Neofx Transfection agent*
- STOP at 24 and 48 hr
- Luciferase/renilla activity detection with Luminometer

3' UTR - ACVR1 and microRNA



Effect of selected microRNA co-transfection on Luciferase activity



Reporter gene activity in HeLa

miR-152 stable decrease
miR-182 transient decrease

miR-381 transient increase
miR-384 transient increase
miR-365 transient increase

miR-148a mild decrease
miR-148b mild decrease

miR-30c/30d/30e no effect
miR-26a no effect

- We have found that the 3' *UTR* of *ACVR1* can be target of post-transcriptional regulation (see reporter gene activity of empty pGL3-prom vector vs pGL3-prom + 3' *UTR* of *ACVR1*).
- We have found that microRNA can have both a positive and negative effect on *ACVR1* expression as assessed by gene reporter activity.

Moreover...

The regulation of mRNA stability and translation are essential in the control of gene expression and regulation of these two processes allows a cell to rapidly respond to changes in intracellular and extracellular stimuli.

A number of sequence elements control the stability/availability of a mRNA either by stimulating or inhibiting degradation. Most of these elements are located in the 3' *UTR* end of the genes.

Among these modulating elements, in mammalian cells the sequence elements rich in adenosine and uridine, called **AU-rich elements (AREs)**, were identified by their ability to target host mRNAs towards rapid degradation.

ACVR1 3' UTR and ARE sequences

The 3' UTR sequence of the ACVR1 gene is classified as containing a Class I Cluster 5 ARE

| | | | | | |
|--------------------|--------------------|------------|--------------------|---------------------|------|
| CATTTTCATA | GTGTCAAGAA | GGAAGATTTG | ACGTTGTTGT | CATTGTCCAG | 50 |
| CTGGGACCTA | ATGCTGGCCT | GACTGGTTGT | CAGAATGGAA | TCCATCTGTC | 100 |
| TCCCTCCCA | AATGGCTGCT | TTGACAAGGC | AGACGTCGTA | CCCAGCCATG | 150 |
| TGTTGGGGAG | ACATCAAAAC | CACCCTAACC | TCGCTCGATG | ACTGTGAACT | 200 |
| GGGCATTTCA | CGAACTGTTT | ACACTGCAGA | GACTAATGTT | GGACAGACAC | 250 |
| TGTTGCAAAG | GTAGGGACTG | GAGGAACACA | GAGAAATCCT | AAAAGAGATC | 300 |
| TGGGCATTAA | GTCAGTGGCT | TTGCATAGCT | TTCACAAGTC | TCCTAGACAC | 350 |
| TCCCCACGGG | AAACTCAAGG | AGGTGGTGAA | TTTTTAATCA | GCAATATTGC | 400 |
| CTGTGCTTCT | CTTCTTTATT | GCACTAGGAA | TTCTTTGCAT | TCCTTACTTG | 450 |
| CACTGTTACT | CTTAATTTTA | AAGACCCAAC | TTGCCAAAAT | GTTGGCTGCG | 500 |
| TACTCCACTG | GTCTGTCTTT | GGATAATAGG | AATTCAATTT | GGCAAAACAA | 550 |
| AATGTAATGT | CAGACTTTGC | TGCATTTTAC | ACATGTGCTG | ATGTTTACAA | 600 |
| TGATGCCGAA | CATTAGGAAT | TGTTTATACA | CAACTTTGCA | AATT ATTTA T | 650 |
| TACTTGTGCA | CTTAGTAGTT | TTTACAAAAC | TGCTTTGTGC | ATATGTTAAA | 700 |
| GCTTATTTTT | ATGTGGTCTT | ATGATTTTAT | TACAGAAATG | TTTTTAACAC | 750 |
| TATACTCTAA | AATGGACATT | TTCTTTTATT | ATCAGTTAAA | ATCACATTTT | 800 |
| AAGTGCTTCA | CATTTGTATG | TGTGTAGACT | GTAACTTTTT | TTCAGTTCAT | 850 |
| ATGCAGAACG | TATTTAG CCA | TTACCCACGT | GACACCACCG | AATATATTAC | 900 |
| TGATTTA GAA | GCAAAGATTT | CAGTAGAATT | TTAGTCCTGA | ACGCTACGGG | 950 |
| GAAAATGCAT | TTTCTTCAGA | ATTATCCATT | ACGTGC ATTT | AAACT CTGCC | 1000 |
| AGAAAAAAT | AACTATTTTG | TTTTAATCTA | CTTTTTGT AT | TTAGT AGTTA | 1050 |
| TTTGTATAAA | TTAAATAAAC | TGTTTTCAAG | TCAAAaaaaa | aaaaaaaaaa | 1100 |

Class I several dispersed copies of the **AUUUA** motif.

Class II at least 2 overlapping UUAUUUA(U/A)(U/A) nonamers (citokines...).

Class III much less defined, they are U-rich regions but contain no AUUUA pentamer.

Modular structure of *ACVR1* 3'UTR sequence

```

CATTTCATA GTGTCAAGAA GGAAGATTG ACGTTGTTGT CATTGTCCAG 50
CTGGGACCTA ATGCTGGCCT GACTGGTTGT CAGAATGGAA TCCATCTGTC 100
TCCCTCCCCA AATGGCTGCT TTGACAAGGC AGACGTCGTA CCCAGCCATG 150
TGTTGGGGAG ACATCAAAAC CACCCTAACC TCGCTCGATG ACTGTGAACT 200
miR-365
GGGCATTTCA CGAACTGTTC ACACTGCAGA GACTAATGTT GGACAGACAC 250
TGTTGCCAAAG GTAGGGACTG GAGGAACACA GAGAAATCCT AAAAGAGATC 300
miR-365
TGGGCATTAA GTCAGTGGCT TTGCATAGCT TTCACAAGTC TCCTAGACAC 350
miR-137
TCCCCACGGG AAACTCAAGG AGGTGGTGAA TTTTAAATCA GCAATATTGC 400
miR-130a/b miR-384 miR130/301/148/152
CTGTGCTTCT CTTCTTTATT GCACTAGGAA TTCTTTGCAT TCCTTACTTG 450
miR-182
CACTGTTACT CTTAATTTTA AAGACCCAAC TTGCCAAAAT GTTGGCTGCG 500
miR-384
TACTCCACTG GTCTGTCTTT GGATAATAGG AATTCAATTT GCCAAACAA 550
miR-30c/d/e
AATGTAATGT CAGACTTTGC TGCATTTTAC ACATGTGCTG ATGTTTACAA 600
miR-384
TGATGCCGAA CATTAGGAAT TGTTTATACA CAACTTTGCA AATTATTTAT 650
TACTTGTGCA CTTAGTAGTT TTTACAAAAC TGCTTTGTGC ATATGTTAAA 700
GCTTATTTTT ATGTGGTCTT ATGATTTTAT TACAGAAATG TTTTAAACAC 750
TATACTCTAA AATGGACATT TTCTTTTATT ATCAGTTAAA ATCACATTTT 800
miR-381/300
AAGTGCTTCA CATTTGTATG TGTGTAGACT GTAACTTTTT TTCAGTTCAT 850
ATGCAGAACG TATTTAGCCA TTACCCACGT GACACCACCG AATATATTAC 900
TGATTTAGAA GCAAAGATTT CAGTAGAATT TTAGTCCTGA ACGCTACGGG 950
GAAAATGCAT TTTCTTCAGA ATTATCCATT ACGTGCATTT AAACTCTGCC 1000
miR-381/300
AGAAAAAAT AACTATTTTG TTTTAAATCTA CTTTTTGTAT TTAGTAGTTA 1050
TTTGTATAAA TTAAATAAAC TGTTTTCAAG TCAAaaaaa aaaaaaaaaa 1100

```

microRNA and ARE interacting protein can compete for the binding to the *ACVR1* 3'UTR sequence.

ARE sequences have a destabilizing effect of *ACVR1* mRNA. This can be counteracted in some conditions by the binding of specific miRNA.

**Istituto G. Gaslini
Genova**

Serena Cappato
Dr Marzia Mura
Dr Anwar Baban
Prof. Roberto Ravazzolo
S.C. Genetica Molecolare e Citogenetica

Dr Maja Di Rocco
U.O. Pediatria II

**Center for Advanced Biotechnology (CBA)
Genova**

Dr Sara Tavella
Laboratory of Regenerative Medicine

Acknowledgements

We thank the patients and their families and in particular we are grateful to the **"FOP Italia Association"** for their fundamental help and their enthusiastic support to our work.

We acknowledge the contribution of Dr M. Lerone, Dr M.T. Divizia, Dr . Alpigiani, Dr M.C. Schiaffino, Prof G. Ferraccioli, Dr. Paola Ferrari who referred patients.